(Removes incorrect reference to aim of the study in paragraph 2, corrects drug to lamivudine not rilpivirine and removes reference to once-daily tablet in paragraph 3)
June 14 (Reuters) - GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.
The studies were designed to evaluate the safety and efficacy of the two-drug combination.
The safety results for the new HIV treatment, which combines drugs dolutegravir and lamivudine, were consistent with the product labelling for the medicines, GSK’s majority owned ViiV Healthcare said. (Reporting by Arathy S Nair in Bengaluru Editing by Alexander Smith)